Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age

NCT01193920 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

380

Enrollment

INDUSTRY

Sponsor class

Conditions

Streptococcal Infections

Interventions

BIOLOGICAL: Group B Streptococcus Trivalent Vaccine - 20/20/20 μg
OTHER: Saline solution
BIOLOGICAL: Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg
BIOLOGICAL: Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg
BIOLOGICAL: Group B Streptococcus Trivalent Vaccine - 5/5/5 μg
OTHER: saline solution

Sponsor

Novartis Vaccines